Episodes

  • Dalbavancin/Oritavancin for treatment of PJI Part 2
    Jan 6 2026

    Join hosts Jessica Seidelman, MD and Johannes Plate, MD, PhD as they continue the in-depth discussion on long-lasting antibiotics with Vance Fowler,MD, MHS, Thomas Holland, and Thomas Lodise, PharmD, PhD in the second episode of this three-part series. Thanks to Osteal Therapeutics for sponsoring this episode.For more information about VT-X7, including the APEX clinical trials results, please visit Ostealtx.com

    FOLLOW us on X @jointapproach or Instagram @jointapproachpodcast for more announcements and content, and reach out to us at jointapproachpodcast@gmail.com

    Show More Show Less
    23 mins
  • Dalbavancin/Oritavancin for Treatment of PJI Part 1
    Dec 16 2025

    Join hosts Jessica Seidelman, MD and Johannes Plate, MD, PhD as they have an in-depth discussion about long-lasting antibiotics with Vance Fowler, MD, MHS, Thomas Holland, MD, and Thomas Lodise, PharmD, PhD in the first episode of this three-part series. Thanks to Osteal Therapeutics for sponsoring this episode. For more information about VT-X7, including the APEX clinical trials results, please visit Ostealtx.com

    FOLLOW us on X @jointapproach or Instagram @jointapproachpodcast for more announcements and content, and reach out to us at jointapproachpodcast@gmail.com

    Show More Show Less
    25 mins
  • The Psychosocial Impact of Orthopedic Joint Infections
    Dec 2 2025

    In this follow-up conversation from the International Consensus Meeting on Infection, hosts Jessica Seidelman, MD and Johannes Plate, MD, PhD chat with Allison Lastinger, MD, FACP, and Ran Schwarzkopf, MD about the question: "How can we capture the physical and psychological impact of orthopedic infections on patients?"

    FOLLOW us on X @jointapproach or Instagram @jointapproachpodcast for more announcements and content, and reach out to us at jointapproachpodcast@gmail.com

    Show More Show Less
    34 mins
  • Spinal Implant Infections Part 2
    Nov 18 2025

    Hosts Jessica Seidelman, MD and Johannes Plate, MD, PhD conclude the discussion on spinal implant infections with Geno Tai, MD, and Francis Lovecchio, MD. Thanks to Osteal Therapeutics for sponsoring this episode. For more information about VT-X7, including the APEX clinical trials results, please visit Ostealtx.com

    FOLLOW us on X @jointapproach or Instagram @jointapproachpodcast for more announcements and content, and reach out to us at jointapproachpodcast@gmail.com

    Show More Show Less
    34 mins
  • Spinal Implant Infections Part 1
    Nov 4 2025

    Join hosts Jessica Seidelman, MD and Johannes Plate, MD, PhD as they discuss spinal implant infections with Gino Tai, MD, and Francis Lovecchio, MD in part 1 of this 2 part series. Thanks to Osteal Therapeutics for sponsoring this episode. For more information about VT-X7, including the APEX clinical trials results, please visit Ostealtx.com

    FOLLOW us on X @jointapproach or Instagram @jointapproachpodcast for more announcements and content, and reach out to us at jointapproachpodcast@gmail.com

    Show More Show Less
    35 mins
  • Bugged and Baffled: A Case with Angela Hewlett and Curtis Hartman
    Oct 22 2025

    Join hosts Jessica Seidelman, MD and Johannes Plate, MD, PhD in this Case Study Series entitled Bugged and Baffled. In this episode, they discuss a challenging case with Angela Hewlett, MD, and Curtis Hartman, MD.

    Thanks to Biocomposites for sponsoring this episode. For more information about Biocomposites products STIMULAN®, NanoBone®, and genex®, please click here

    FOLLOW us on X @jointapproach or Instagram @jointapproachpodcast for more announcements and content, and reach out to us at jointapproachpodcast@gmail.com

    Show More Show Less
    35 mins
  • Innovative Approaches to Bone and Joint Infections Part 3
    Oct 7 2025

    Host Jessica Seidelman, MD and guests Kerry LaPlante, Pharm.D., FCCP, FIDSA, FIDP, and Julie Ann Justo, Pharm.D. conclude this 3-part series with discussions on pipeline innovations and adjunctive strategies for treating challenging prosthetic joint infections. Topics include local antibiotic administration, phage therapy, and immunotherapy. Thanks to Osteal Therapeutics for sponsoring this episode. For more information about VT-X7, including the APEX clinical trials results, please visit Ostealtx.com

    Listen to Breakpoints: The SIDP Podcast

    References:

    "Antibiotic Therapy for 6 or 12 Weeks for Prosthetic Joint Infection" PMID 34042388

    "NDM-9 resistance to taniborbactam" PMID 36796395

    "Wide dissemination of Gram-negative bacteria producing the taniborbactam-resistant NDM-9 variant: a One Health concern" PMID 37394537

    IDSA 2024 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections https://www.idsociety.org/practice-guideline/amr-guidance/

    "Dalbavancin for the Treatment of Osteomyelitis in Adult Patients: A Randomized Clinical Trial of Efficacy and Safety" PMID 30648126

    "Corynebacterium striatum Prosthetic Joint Infection Successfully Treated with Long-Term Dalbavancin" PMID 36985124

    "Emergence of Dalbavancin, Vancomycin, and Daptomycin Nonsusceptible Staphylococcus aureus in a Patient Treated with Dalbavancin: Case Report and Isolate Characterization" PMID 35510938

    "Local antibiotic delivery via intra-articular catheter infusion for the treatment of periprosthetic joint infection: a systematic review" PMID 38691147

    "A High-Affinity Native Human Antibody Disrupts Biofilm from Staphylococcus aureus Bacteria and Potentiates Antibiotic Efficacy in a Mouse Implant Infection Model" PMID 26833157

    Show More Show Less
    31 mins
  • Innovative Approaches to Bone and Joint Infections Part 2
    Sep 23 2025

    Host Jessica Seidelman, MD and guests Kerry LaPlante, Pharm.D., FCCP, FIDSA, FIDP, and Julie Ann Justo, Pharm.D. continue discussing long-acting antibiotics, systemic vs. oral antibiotics, and drug and dosing perspectives in episode 2 of this 3-part conversation. This episode is sponsored by BONESUPPORT™, makers of CERAMENT® G with Gentamicin. CERAMENT G is an FDA-designated breakthrough device offering proven bone remodeling with reliable elution of broad-spectrum Gentamicin. CERAMENT G has a 96% success rate in eradication of infection in a single-stage for patients with fracture related infections and chronic osteomyelitis. To learn more and review CERAMENT G cases, visit their website at BONESUPPORT.com

    Listen to Breakpoints: The SIDP Podcast

    References:

    "Antibiotic Therapy for 6 or 12 Weeks for Prosthetic Joint Infection" PMID 34042388

    "NDM-9 resistance to taniborbactam" PMID 36796395

    "Wide dissemination of Gram-negative bacteria producing the taniborbactam-resistant NDM-9 variant: a One Health concern" PMID 37394537

    IDSA 2024 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections https://www.idsociety.org/practice-guideline/amr-guidance/

    "Dalbavancin for the Treatment of Osteomyelitis in Adult Patients: A Randomized Clinical Trial of Efficacy and Safety" PMID 30648126

    "Corynebacterium striatum Prosthetic Joint Infection Successfully Treated with Long-Term Dalbavancin" PMID 36985124

    "Emergence of Dalbavancin, Vancomycin, and Daptomycin Nonsusceptible Staphylococcus aureus in a Patient Treated with Dalbavancin: Case Report and Isolate Characterization" PMID 35510938

    "Local antibiotic delivery via intra-articular catheter infusion for the treatment of periprosthetic joint infection: a systematic review" PMID 38691147

    "A High-Affinity Native Human Antibody Disrupts Biofilm from Staphylococcus aureus Bacteria and Potentiates Antibiotic Efficacy in a Mouse Implant Infection Model" PMID 26833157

    FOLLOW us on X @jointapproach or Instagram @jointapproachpodcast for more announcements and content, and reach out to us at jointapproachpodcast@gmail.com

    Show More Show Less
    25 mins